Sorafenib plus paclitaxel metronomic chemotherapy in adreno-cortical-carcinoma patients progressing after 1st or snd line cytotoxic chemotherapy - PAXO

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2008-000759-91-IT

Enrollment

Registered

2008-07-28

Start date

2008-04-24

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ACC MedDRA version: 9.1 Level: SOC Classification code 10014698 Term: Endocrine disorders MedDRA version: 9.1 Level: LLT Classification code 10001326 Term: Adrenal carcinoma

Interventions

Trade Name: NEXAVAR*112CPR RIV 200MG Pharmaceutical Form: Tablet INN or Proposed INN: sorafenib Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Trade Name: T

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - histologically confirmed diagnosis of ACC - locally advanced or metastatic disease not amenable to radical surgery resection Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: - history of prior malignancy - severe renal insufficiency

Design outcomes

Primary

Measure	Time frame
Main Objective: To determine the activity and side effects of Sorafenib plus weekly Paclitaxel;Secondary Objective: To assess che clinical benefit as misured by a non progressing rate after 4 months;Primary end point(s): - survival without disease mprogression	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026